BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 1/29
BIOMEDICA free soluble RANKL ELISA - References/Publications
free sRANKL High Sensitivity ELISA REFERENCES published after 2015, using assay #BI-20462
1. Substrate Microarchitecture Shapes the Paracrine Crosstalk of Stem Cells with
Endothelial Cells and Osteoblasts
Francisco Martín-Saavedra, Lara Crespo, Clara Escudero-Duch, Laura Saldaña,
Enrique Gómez-Barrena, and Nuria Vilaboa
Sci Rep. 2017; 7: 15182.
PMCID: PMC5680323
2. Paracrine interactions between mesenchymal stem cells and macrophages are
regulated by 1,25-dihydroxyvitamin D3
Laura Saldaña, Gema Vallés, Fátima Bensiamar, Francisco José Mancebo,
Eduardo García-Rey, and Nuria Vilaboa
Sci Rep. 2017; 7: 14618.
PMCID: PMC5668416
3. Aberrant regulation of RANKL/OPG in women at high risk of developing breast
cancer
Stefan Kiechl, Daniel Schramek, Martin Widschwendter, Evangelia-Ourania
Fourkala, Alexey Zaikin, Allison Jones, Bernadette Jaeger, Brigitte Rack,
Wolfgang Janni, Christoph Scholz, Johann Willeit, Siegfried Weger, Agnes Mayr,
Andrew Teschendorff, Adam Rosenthal, Lindsay Fraser, Susan Philpott, Louis
Dubeau, Mohammed Keshtgar, Rebecca Roylance, Ian J. Jacobs, Usha Menon,
Georg Schett, Josef M. Penninger
Oncotarget, 2017, 3811-3825.
PMID: 28002811
4. Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant
patients
Uwe Lange, Katharina Classen, Ulf Müller-Ladner, Manfred Richter
Clinical Transplantation, 2017.
PMID: 28940569
5. Combined bioavailable isoflavones and probiotics improve bone status and
estrogen metabolism in postmenopausal osteopenic women: a randomized
controlled trial
Max Norman Tandrup Lambert, Catrine Bundgaard Thybo, Simon Lykkeboe, Lars
Melholt Rasmussen, Xavier Frette, Lars Porskjær Christensen, Per Bendix
Jeppesen
The American Journal of Clinical Nutrition, 2017, 909-920.
PMID: 28768651
6. Association of Circulating Osteoprotegerin (OPG) and RANKL with Intracranial
Arterial Calcification in Hypertensive Patients.
Cheng Y., Wang Y. , Guo Q. , Zhu D. , Li Y.
Journal of Hypertension, 2017.
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 2/29
7. Effects of short-term dry immersion on bone remodeling markers, insulin and
adipokines
Marie-Thérèse Linossier , Liubov E. Amirova, Mireille Thomas, Myriam Normand,
Marie-Pierre Bareille, Guillemette Gauquelin-Koch, Arnaud Beck, Marie-Claude
Costes-Salon, Christine Bonneau, Claude Gharib, Marc-Antoine Custaud,
Laurence Vico
PLOS One, 2017.
PMID: 28806419
8. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing
Ewa Śliwicka, Tomasz Cisoń, Zbigniew Kasprzak, Alicja Nowak, and Łucja
Pilaczyńska-Szcześniak
PLoS One. 2017; 12(7): e0181259.
PMCID: PMC5521782
9. Methotrexate and low-dose prednisolone downregulate osteoclast function by
decreasing receptor activator of nuclear factor-κβ expression in monocytes from
patients with early rheumatoid arthritis
Inês Pedro Perpétuo, Joana Caetano-Lopes, Ana Maria Rodrigues, Raquel
Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João
Eurico Fonseca
RMD Open. 2017; 3(1): e000365.
PMCID: PMC5604603
10. Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype:
Results from the EPIC cohort
Danja Sarink, Helena Schock, Theron Johnson, Kim Overvad, Marianne Holm,
Anne Tjønneland, Marie-Christine Boutron-Ruault, Mathilde His, Marina Kvaskoff,
Heiner Boeing, Pagona Lagiou, Eleni-Maria Papatesta, Antonia Trichopoulou,
Domenico Palli, Valeria Pala, Amalia Mattiello, Rosario Tumino, Carlotta
Sacerdote, H.B(as) Bueno-de-Mesquita, Carla H van Gils, Petra H Peeters,
Elisabete Weiderpass, Antonio Agudo, Maria-José Sánchez, Maria-Dolores
Chirlaque, Eva Ardanaz, Pilar Amiano, Kay Tee Khaw, Ruth Travis, Laure Dossus,
Mark Gunter, Sabina Rinaldi, Melissa Merritt,16 Elio Riboli,16 Rudolf Kaaks,1 and
Renée T. Fortner
Cancer Prev Res (Phila). 2017 Sep; 10(9): 525–534.
PMCID: PMC5603271
11. Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral
Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional
Observational Study
Barbara Hauser, Sizheng Zhao, Micaela R. Visconti, Philip L. Riches, William D.
Fraser, Isabelle Piec, Nicola J. Goodson, and Stuart H. Ralston
Calcif Tissue Int. 2017; 101(4): 375–383.
PMCID: PMC5587630
12. Changes in RANKL during the first two years after cART initiation in HIV-infected
cART naïve adults
Inger Hee Mathiesen, Mohammad Salem, Jan Gerstoft, Julie Christine Gaardbo,
Niels Obel, Court Pedersen, Henrik Ullum, Susanne Dam Nielsen, and Ann-Brit Eg
Hansen
BMC Infect Dis. 2017; 17: 262.
PMCID: PMC5387326
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 3/29
13. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for
Charcot arthropathy development
Bożena Bruhn-Olszewska, Anna Korzon-Burakowska, Grzegorz Węgrzyn, and
Joanna Jakóbkiewicz-Banecka
Sci Rep. 2017; 7: 501.
PMCID: PMC5428699
14. Markers of bone metabolism during 14 days of bed rest in young and older men
J. Buehlmeier, P. Frings-Meuthen, N. Mohorko, P. Lau, S. Mazzucco, J.L. Ferretti,
G. Biolo, R. Pisot, B. Simunic, and J. Rittweger
J Musculoskelet Neuronal Interact. 2017 Mar; 17(1): 399–408.
PMCID: PMC538376
15. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in
Rheumatoid Arthritis
Inês P. Perpétuo, Joana Caetano-Lopes, Ana Maria Rodrigues, Raquel
Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João E.
Fonseca
Biomed Res Int. 2017; 2017: 2690402.
PMCID: PMC5327780
16. Ankylosing Spondylitis Patients Have Impaired Osteoclast Gene Expression in
Circulating Osteoclast Precursors
Inês P. Perpétuo, Joana Caetano-Lopes, Elsa Vieira-Sousa, Raquel Campanilho-
Marques, Cristina Ponte, Nikita Khmelinskii, Helena Canhão, Mari Ainola, and
João E. Fonseca
Front Med (Lausanne). 2017; 4: 5.
PMCID: PMC5269449
17. NOTCH1 Mutations in Aortic Stenosis: Association with
Osteoprotegerin/RANK/RANKL
Olga Irtyuga, Anna Malashicheva, Ekaterina Zhiduleva, Olga Freylikhman, Oxana
Rotar, Magnus Bäck, Svetlana Tarnovskaya, Anna Kostareva, and Olga Moiseeva
Biomed Res Int. 2017; 2017: 6917907.
PMCID: PMC5299165
18. Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological
Progression in Tightly Controlled Rheumatoid Arthritis
Carmen Gómez-Vaquero, Irene Martín, Estibaliz Loza, Loreto Carmona, José
Ivorra, José Antonio Narváez, Javier Hernández-Gañán, Pedro Alía, and Javier
Narváez
PLoS One. 2016; 11(12): e0166691.
PMCID: PMC5135438
19. HAJDU CHENEY SYNDROME; REPORT OF A NOVEL NOTCH2 MUTATION AND
TREATMENT WITH DENOSUMAB
Adami Giovanni, Rossini Maurizio, Gatti Davide, Orsolini Giovanni, Idolazzi Luca,
Viapiana Ombretta, Scarpa Aldo, and Canalis Ernesto
Bone. 2016 Nov; 92: 150–156.
PMCID: PMC5056853
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 4/29
20. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in
Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease
Ludmila Ugay, Evgenia Kochetkova, Vera Nevzorova, and Yuliya Maistrovskaia
Chin Med J (Engl). 2016 Jul 20; 129(14): 1696–1703.
PMCID: PMC4960959
21. THU0477 Effect of Recent Spinal Cord Injury on the OPG/RANKL System and Its
Relationship with Bone Loss and Antiosteoporotic Response To Denosumab
Therapy. Preliminary Results
L. Gifre, J. Vidal, S. Ruiz-Gaspà, E. Portell, A. Monegal, A. Muxi, N. Guañabens, P.
Peris
Annals of the Rheumatic Diseases, 06.2016.
PMID: 28580511
22. THU0476 Efficacy of Denosumab for The Treatment of Osteoporosis in Japanese
Patients with Rheumatoid Arthritis
K. Oh, O. Namiki, Y. Toyoshima, K. Inagaki, K. Kanbe, J. Chiba
Annals of the Rheumatic Diseases, 06.2016.
PMID: 26585988
23. Path Analysis Identifies Receptor Activator of Nuclear Factor-B Ligand,
Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone
Erosion Relationship in Gout
Ashika Chhana, Opetaia Aati, Gregory D. Gamble, Karen E. Callon, Anthony J.
Doyle, Mark Roger, Fiona M. McQueen, Anne Horne, Ian R. Reid, Jillian Cornish,
and Nicola Dalbeth
J Rheumatol, Feb 2016; 43: 445 - 449.
24. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid
arthritis
Sara Remuzgo-Martínez, Fernanda Genre, Raquel López-Mejías, Begoña Ubilla,
Verónica Mijares, Trinitario Pina, Alfonso Corrales, Ricardo Blanco, Javier Martín,
Javier Llorca, and Miguel A. González-Gaya
Sci Rep. 2016; 6: 29713.
PMCID: PMC4940734
25. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal
study
Helena Schock, Anne Zeleniuch-Jacquotte, Eva Lundin, Kjell Grankvist, Hans-Åke
Lakso, Annika Idahl, Matti Lehtinen, Heljä-Marja Surcel, and Renée T. Fortner
BMC Pregnancy Childbirth. 2016; 16: 146.
PMCID: PMC4932669
26. Toward improved phosphorus efficiency in monogastrics—interplay of serum,
minerals, bone, and immune system after divergent dietary phosphorus supply in
swine
Michael Oster, Franziska Just, Kirsten Büsing, Petra Wolf, Christian Polley, Brigitte
Vollmar, Eduard Muráni, Siriluck Ponsuksili, and Klaus Wimmers
Am J Physiol Regul Integr Comp Physiol. 2016 May 15; 310(10): R917–R925.
PMCID: PMC4896080
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 5/29
27. Denosumab versus zoledronic acid in patients previously treated with zoledronic
acid.
Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I,
Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
Osteoporos Int. 2015 Oct;26(10):2521-7.
PMID: 25990355
28. Notch Signaling Induces Root Resorption via RANKL and IL-6 from hPDL Cells
J. Kikuta, M. Yamaguchi, M. Shimizu, T. Yoshino, and K. Kasai
Journal of Dental Research, Jan 2015; 94: 140-147.
PMID: 25376720
free sRANKL ELISA REFERENCES published before 2015, using assays #BI-20422H, #BI-20452
29. Clinical, instrumental, serological and histological findings suggest that hemophilia
B may be less severe than hemophilia A
Daniela Melchiorre, Silvia Linari, Mirko Manetti, Eloisa Romano, Francesco Sofi,
Marco Matucci-Cerinic, Christian Carulli, Massimo Innocenti, Lidia Ibba-Manneschi,
and Giancarlo Castaman
Haematologica, Feb 2016; 101: 219 - 225.
PMCID: PMC4938330
30. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in
Ankylosing Spondylitis
Inês P. Perpétuo, Rita Raposeiro, Joana Caetano-Lopes, Elsa Vieira-Sousa, Raquel
Campanilho-Marques, Cristina Ponte, Helena Canhão, Mari Ainola, and João E.
Fonseca
PLoS One. 2015; 10(12): e0144655.
PMCID: PMC4682624
31. Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and
sRANKL Concentrations in Patients with Rheumatoid Arthritis
Katharina Kurz, Manfred Herold, Elisabeth Russe, Werner Klotz, Guenter Weiss,
and Dietmar Fuchs
Dis Markers. 2015; 2015: 276969.
PMCID: PMC4631883
32. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a
cross-sectional, observational study
Eva Kulcsar-Jakab, Zsofia Petho, Zoltan Pap, Edit Kalina, Roza Foldesi, Adam
Balogh, Peter Antal-Szalmas, and Harjit Pal Bhattoa
BMC Musculoskelet Disord. 2015; 16: 227.
PMCID: PMC4551745
33. Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone
marrow stromal cells and impairs the resorbing activity of mature osteoclasts
Maria Rita Pitari, Marco Rossi, Nicola Amodio, Cirino Botta, Eugenio Morelli, Cinzia
Federico, Annamaria Gullà, Daniele Caracciolo, Maria Teresa Di Martino,
Mariamena Arbitrio, Antonio Giordano, Pierosandro Tagliaferri, and Pierfrancesco
Tassone
Oncotarget. 2015 Sep 29; 6(29): 27343–27358.
PMCID: PMC4694994
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 6/29
34. Osteoprotegerin is a significant prognostic factor for overall survival in patients
with primary systemic amyloidosis independent of the Mayo staging
E Kastritis, M Gavriatopoulou, M A Dimopoulos, E Eleutherakis-Papaiakovou, N
Kanellias, M Roussou, C Pamboucas, S T Toumanidis, and E Terpos
Blood Cancer J. 2015 Jun; 5(6): e319.
PMCID: PMC4648482
35. Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic
dendritic cells via RANKL secretion
Stéphanie A Demoulin, Joan Somja, Anaëlle Duray, Samuel Guénin, Patrick
Roncarati, Philippe O Delvenne, Michael F Herfs, and Pascale M Hubert
Oncoimmunology. 2015 Jun; 4(6): e1008334.
PMCID: PMC4485731
36. Topographical cues regulate the crosstalk between MSCs and macrophages
Gema Vallés, Fátima Bensiamar, Lara Crespo, Manuel Arruebo, Nuria Vilaboa, and
Laura Saldañaa
Biomaterials. 2015 Jan; 37: 124–133.
PMCID: PMC4245715
37. Denosumab for the prevention of skeletal complications in metastatic castration-
resistant prostate cancer: comparison of skeletal-related events and symptomatic
skeletal events
M. R. Smith, R. E. Coleman, L. Klotz, K. Pittman, P. Milecki, S. Ng, K. N. Chi, A.
Balakumaran, R. Wei, H. Wang, A. Braun, and K. Fizazi
Ann Oncol. 2015 Feb;26(2):368-374.
PMID: 25425475
38. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone
mineral density: changes in bone turnover markers and circulating sclerostin
levels
Eugènia Negredo, Adolfo Diez-Pérez, Anna Bonjoch, Pere Domingo, Núria Pérez-
Álvarez, Mar Gutierrez, Gracia Mateo, Jordi Puig, Patricia Echeverría, Roser Escrig,
and Bonaventura Clotet
J. Antimicrob. Chemother., 2015; 70: 2104-2107
PMID: 25769303
39. Ultrasonographic examination of rheumatoid arthritis patients who are free of
physical synovitis: power Doppler subclinical synovitis is associated with bone
erosion
Shin-ya Kawashiri, Takahisa Suzuki, Yoshikazu Nakashima, Yoshiro Horai,
Akitomo Okada, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Kazuhiko Arima,
Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Kiyoshi Aoyagi, Katsumi
Eguchi, and Atsushi Kawakami
Rheumatology, Mar 2014; 53: 562-569.
PMID: 24319104
40. Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble
tumor necrosis factor receptor use
Mie Jin Lim, Seong Ryul Kwon, Kowoon Joo, Min Jung Son, Shin-Goo Park, and
Won Park
Korean J Intern Med. 2014 Nov; 29(6): 807–813.
PMCID: PMC4219971
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 7/29
41. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis
Kristyna Brabnikova-Maresova, Katerina Jarosova, Karel Pavelka, and Jan J
Stepan
Arthritis Res Ther. 2014; 16(5): 460.
PMCID: PMC4236454
42. Bone mineral status in Egyptian children with classic congenital adrenal
hyperplasia. A single-center study from Upper Egypt
Kotb Abbass Metwalley and Abdel-Rahman Abbdel-Hamed El-Saied
Indian J Endocrinol Metab. 2014 Sep-Oct; 18(5): 700–704.
PMCID: PMC4171895
43. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are
not changed in individuals with high bone mass causing mutations in LRP5
Osteoporos Int. 2014 Oct; 25(10): 2383–2388.
PMCID: PMC4659359
44. Osteoclastogenic Potential of Peripheral Blood Mononuclear Cells in Cleidocranial
Dysplasia
Maria Felicia Faienza, Annamaria Ventura, Laura Piacente, Maria Ciccarelli,
Margherita Gigante, Loreto Gesualdo, Silvia Colucci, Luciano Cavallo, Maria Grano,
and Giacomina Brunetti
Int J Med Sci. 2014; 11(4): 356–364.
PMCID: PMC3936030
45. Relationship between Biochemical Bone Markers and Bone Mineral Density in
Patients with Phenylketonuria under Restricted Diet
Hala M. Koura, Sherif M. Zaki, Nagwa A. Ismail, Emad E. Salama, Dalia H. El
Lebedy, and Laila K. Effat
Iran J Pediatr. 2014 Feb; 24(1): 23–28.
PMCID: PMC4359600
46. Independent relationship of osteoprotegerin concentrations with endothelial
activation and carotid atherosclerosis in patients with severe rheumatoid arthritis.
Patrick H. Dessein, Raquel López-Mejias, Carlos González-Juanatey, Fernanda
Genre, José A. Miranda-Filloy, Javier Llorca, and Miguel A. González-Gay
J Rheumatol, Mar 2014; 41: 429-436.
PMID: 24488413
47. Synovial membrane immunohistology in early-untreated rheumatoid arthritis
reveals high expression of catabolic bone markers that is modulated by
methotrexate
Shankar Revu, Petra Neregård, Erik af Klint, Marina Korotkova, and Anca Irinel
Catrina
Arthritis Res Ther. 2013; 15(6): R205.
PMCID: PMC3978873
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 8/29
48. OPG and sRANKL serum levels and incident hip fracture in postmenopausal
Caucasian women in the Women's Health Initiative Observational Study
Andrea Z. LaCroix, Rebecca D. Jackson, Aaron Aragaki, Charles Kooperberg, Jane
A. Cauley, Zhao Chen, Meryl S. LeBoff, David Duggan, and Jean Wactawski-
Wendeg
Bone. 2013 Oct; 56(2): 10.1016/j.bone.2013.05.018.
PMCID: PMC3832355
49. Juvenile Paget’s Disease In An Iranian Kindred With Vitamin D Deficiency And
Novel Homozygous TNFRSF11B Mutation
Forough Saki, Zohreh Karamizadeh, Shiva Nasirabadi, Steven Mumm, William H.
McAlister, and Michael P. Whyte
J Bone Miner Res. 2013 Jun; 28(6): 1501–1508.
PMID: PMC3663917
50. Osteoprotegerin inhibits bone resorption and prevents tumor development in a
xenogenic model of Ewing's sarcoma by inhibiting RANKL
Gaëlle Picarda, Etienne Matous, Jérôme Amiaud, Céline Charrier, François
Lamoureux, Marie-Françoise Heymann, Franck Tirode, Bruno Pitard, Valérie
Trichet, Dominique Heymann, and Françoise Redini
J Bone Oncol. 2013 Sep; 2(3): 95–104.
PMCID: PMC4723385
51. Human Apolipoprotein E Isoforms differentially affect Bone Mass and Turnover in
vivo
Marco Dieckmann, F. Timo Beil, Brigitte Mueller, Alexander Bartelt, Robert P.
Marshall, Till Koehne, Michael Amling, Wolfgang Ruether, Jackie A. Cooper,6 Steve
E. Humphries, Joachim Herz, and Andreas Niemeier
J Bone Miner Res. 2013 Feb; 28(2): 236–245.
PMCID: PMC3547162
52. Increased vertebral morphometric fracture in patients with postsurgical
hypoparathyroidism despite normal bone mineral density
Maira L Mendonça, Francisco A Pereira, Marcello H Nogueira-Barbosa, Lucas M
Monsignore, Sara R Teixeira, Plauto CA Watanabe, Lea MZ Maciel, and Francisco
JA de Paula
BMC Endocr Disord. 2013; 13: 1.
PMCID: PMC3546901
53. Traditional and Novel Bone Remodeling Markers in Premenopausal and
Postmenopausal Women
Sonsoles Botella, Patricia Restituto, Ignacio Monreal, Inmaculada Colina, Amparo
Calleja, and Nerea Varo
J. Clin. Endocrinol. Metab., Nov 2013; 98: E1740-E1748.
PMID: 24001743
54. Activation of the receptor activator of the nuclear factor-B ligand pathway during
coronary bypass surgery: comparison between on- and off-pump coronary artery
bypass surgery procedures
Antonella Galeone, Giacomina Brunetti, Crescenzia Rotunno, Angela Oranger,
Silvia Colucci, Luigi de Luca Tupputi Schinosa, Alberta Zallone, Maria Grano, and
Domenico Paparella
Eur J Cardiothorac Surg, Aug 2013; 44: e141-e147.
PMID: 23671202
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 9/29
55. An Independent Positive Relationship Between the Serum Total Osteocalcin Level
and Fat-Free Mass in Healthy Premenopausal Women
Jian-min Liu, Hong-yan Zhao, Lin Zhao, Ying Chen, Lian-zhen Zhang, Bei Tao, Li-
hao Sun, Yong-ju Zhao, Wei-qing Wang, Man-yin Xu, Jia-lun Chen, and Guang
Ning
J. Clin. Endocrinol. Metab., May 2013; 98: 2146-2152.
PMID: 23553865
56. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I
degradation by matrix metalloproteinases as assessed by serum 1CTP—a possible
mechanism for specific inhibition of radiological destruction
Inga-Lill Engvall, Björn Svensson, Annelies Boonen, Désirée van der Heijde, Ulf H.
Lerner, Ingiäld Hafström, and on behalf of the BARFOT study group
Rheumatology, Apr 2013; 52: 733-742.
PMID: 23275387
57. High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase
deficiency on chronic glucocorticoid treatment
Giacomina Brunetti, Maria Felicia Faienza, Laura Piacente, Annamaria Ventura,
Angela Oranger, Claudia Carbone, Adriana Di Benedetto, Graziana Colaianni,
Margherita Gigante, Giorgio Mori, Loreto Gesualdo, Silvia Colucci, Luciano Cavallo,
and Maria Grano
Am J Physiol Endocrinol Metab, Mar 2013; 304: E546 - E554.
PMID: 23299503
58. Receptor Activator for NF-B Ligand in Acute Myeloid Leukemia: Expression,
Function, and Modulation of NK Cell Immunosurveillance
Benjamin Joachim Schmiedel, Tina Nuebling, Julia Steinbacher, Alexandra
Malinovska, Constantin Maximilian Wende, Miyuki Azuma, Pascal Schneider,
Ludger Grosse-Hovest, and Helmut Rainer Salih
J. Immunol., Jan 2013; 190: 821 - 831.
PMID: 23241893
59. Bone metabolism compensates for the delayed growth in small for gestational age
neonates
Roxane Tenta, Ifigeneia Bourgiezi, Evangelos Aliferis, Magdalini Papadopoulou,
Antonis Gounaris, and Maria Skouroliakou
Organogenesis. 2013 Jan 1; 9(1): 55–59.
PMCID: PMC3674041
60. Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and
Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A
Randomized, Head-to-Head Clinical Trial
Athanasios D. Anastasilakis, Stergios A. Polyzos, Athina Gkiomisi, Ilias Bisbinas,
Spyridon Gerou, and Polyzois Makras
J. Clin. Endocrinol. Metab., 2013; 98: 3206-3212.
PMID: 23788684
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 10/29
61. Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with
bisphosphonates alone or in combination with pitavastatin over an 18-month
follow-up after more than 4 years of treatment with bisphosphonates
Masakazu Nagashima, Hiroshi Takahashi, Kenichi Shimane, Yuichi Nagase, and
Koichi Wauke
Arthritis Res Ther. 2012; 14(5): R224.
PMCID: PMC3580535
62. Changes of Serum Soluble Receptor Activator for Nuclear Factor-κB Ligand after
Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts
Kaneko K, Kusunoki N, Hasunuma T, Kawai S.
The Journal of Clinical Endocrinology and Metabolism. 2012;97(10):E1909-E1917.
PMCID: PMC3462941
63. Vertebral fractures in patients with inflammatory bowel disease COMPARED with a
healthy population: a prospective case-control study
Vázquez MA, Lopez E, Montoya MJ, Giner M, Pérez-Temprano R, Pérez-Cano R.
BMC Gastroenterology. 2012;12:47.
PMCID: PMC3438096
64. The relationship between osteoclastogenic and anti-osteoclastogenic pro-
inflammatory cytokines differs in human osteoporotic and osteoarthritic bone
tissues
Zupan J, Komadina R, Marc J.
Journal of Biomedical Science. 2012;19(1):28.
PMCID: PMC3307025
65. Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in
Multiple Myeloma
Clive Henry Buckle, Evy De Leenheer, Michelle Anne Lawson, Kwee Yong, Neil
Rabin, Mark Perry, Karen Vanderkerken, and Peter Ian Croucher
PLoS ONE. 2012;7(8):e41127.
PMCID: PMC3430669
66. Changes of Serum Soluble Receptor Activator for Nuclear Factor-B Ligand after
Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts
Kaichi Kaneko, Natsuko Kusunoki, Tomoko Hasunuma, and Shinichi Kawai
J. Clin. Endocrinol. Metab., Oct 2012; 97: E1909 - E1917.
PMCID: PMC3462941
67. Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell
Histiocytosis
Polyzois Makras, Stergios A. Polyzos, Athanasios D. Anastasilakis, Evangelos
Terpos, George Kanakis, Marian Schini, Athanasios Papatheodorou, and Gregory
A. Kaltsas
J. Clin. Endocrinol. Metab., Apr 2012; 97: E618 - E621.
PMID: 22278426
68. Diets Higher in Dairy Foods and Dietary Protein Support Bone Health during Diet-
and Exercise-Induced Weight Loss in Overweight and Obese Premenopausal
Women
Andrea R. Josse, Stephanie A. Atkinson, Mark A. Tarnopolsky, and Stuart M.
Phillips
J. Clin. Endocrinol. Metab., Jan 2012; 97: 251 - 260.
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 11/29
PMID: 22049177
69. First inducible transgene expression in porcine large animal models
Nikolai Klymiuk, Wolfgang Böcker, Veronika Schönitzer, Andrea Bähr, Tamara
Radic, Thomas Fröhlich, Annegret Wünsch, Barbara Keßler, Mayuko Kurome,
Eleonore Schilling, Nadja Herbach, Rüdiger Wanke, Hiroshi Nagashima, Wolf
Mutschler, Georg J. Arnold, Reinhard Schwinzer, Matthias Schieker, and Eckhard
Wolf
FASEB J, Mar 2012; 26: 1086 - 1099.
PMID: 22138035
70. Evolution of coronary artery calcification in patients with chronic kidney disease
Stages 3 and 4, with and without diabetes
Aristeidis Stavroulopoulos, Christine J. Porter, Kate Pointon, John M. Monaghan,
Simon D. Roe, and Michael J.D. Cassidy
Nephrol. Dial. Transplant., Aug 2011; 26: 2582 - 2589.
PMID: 21224493
71. RANKL Is a Downstream Mediator for Insulin-Induced Osteoblastic Differentiation
of Vascular Smooth Muscle Cells
Ling-Qing Yuan, Jia-Hua Zhu, Hua-Wen Wang, Qiu-Hua Liang, Hui Xie, Xian-Ping
Wu, Hua Zhou, Rong-Rong Cui, Zhi-Feng Sheng, Hou-De Zhou, Xiao Zhu, Guan-
Ying Liu, You-Shuo Liu, and Er-Yuan Liao
PLoS ONE. 2011;6(12):e29037.
PMCID: PMC3240644
72. Correlation of Circulating Omentin-1 with Bone Mineral Density in Multiple
Sclerosis: The Crosstalk between Bone and Adipose Tissue
Majid Assadi, Hooman Salimipour, Samad Akbarzadeh, Reza Nemati, Syed
Mojtaba Jafari, Afshar Bargahi, Zahra Samani, Mohammad Seyedabadi, Zahra
Sanjdideh, and Iraj Nabipour
PLoS ONE. 2011;6(9):e24240.
PMCID: PMC3174149
73. The RANKL/RANK/OPG Signaling Pathway Mediates Medial Arterial Calcification in
Diabetic Charcot Neuroarthropathy
Agbor Ndip, Alfred Williams, Edward B. Jude, Ferdinand Serracino-Inglott, Steve
Richardson, J.V. Smyth, Andrew J.M. Boulton, and M. Yvonne Alexander
Diabetes, Aug 2011; 60: 2187 - 2196.
PMCID: PMC3142088
74. Serum osteoprotegerin levels are related to height loss: The Tromsø Study
Jørgensen L, Hansen J-B, Brox J, Mathiesen E, Vik A, Jacobsen BK.
European Journal of Epidemiology. 2011;26(4):305-312.
PMCID: PMC3088831
75. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with
type 2 diabetes mellitus
Jong Suk Park, Min Ho Cho, Ji Sun Nam, Jeong Seon Yoo, Chul Woo Ahn, Bong
Soo Cha, Kyung Rae Kim, and Hyun Chul Lee
Eur. J. Endocrinol., Jan 2011; 164: 69 - 74.
PMCID: PMC3000683
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 12/29
76. Circulating osteoprotegerin and soluble receptor activator of nuclear factor B
ligand in polycystic ovary syndrome: relationships to insulin resistance and
endothelial dysfunction
Carmen Emanuela Pepene, Ioana Rada Ilie, Ioan Marian, and Ileana Duncea
Eur. J. Endocrinol., Jan 2011; 164: 61 - 68.
PMID: 20974706
77. Dissociation of Osteogenic and Immunological Effects by the Selective
Glucocorticoid Receptor Agonist, Compound A, in Human Bone Marrow Stromal
Cells.
Martina Rauner, Claudia Goettsch, Nicola Stein, Sylvia Thiele, Martin Bornhaeuser,
Karolien De Bosscher, Guy Haegeman, Jan Tuckermann, and Lorenz C. Hofbauer
Endocrinology, Jan 2011; 152: 103 - 112.
PMID: 21084452
78. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB
(sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and
osteoprotegerin (OPG) during proximal humerus fracture healing
Alessandra Colombini, Giovanni Lombardi, Emanuela Galliera, Giada Dogliotti,
Pietro Randelli, Alexander Meerssemann, Giuseppe Mineo, Paolo Cabitza, and
Massimiliano Marco Corsi
International Orthopaedics. 2011;35(5):777-782.
PMCID: PMC3080502
79. Circulating osteoprotegerin and soluble receptor activator of nuclear factor B
ligand in polycystic ovary syndrome: relationships to insulin resistance and
endothelial dysfunction.
Carmen Emanuela Pepene, Ioana Rada Ilie, Ioan Marian, and Ileana Duncea
Eur. J. Endocrinol., Jan 2011; 164: 61 - 68.
PMID: 20974706
80. Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
Wasilewska A, Rybi-Szuminska A, Zoch-Zwierz W.
Pediatric Nephrology. 2010;25(10):2067-2075.
PMCID: PMC2923718
81. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict
annual radiological progression over 11 years in rheumatoid arthritis.
Lilian H D van Tuyl, Alexandre E Voskuyl, Maarten Boers, Piet Geusens, Robert B
M Landewé, Ben A C Dijkmans, and Willem F Lems
Ann Rheum Dis, Sep 2010; 69: 1623 - 1628.
PMID: 20525836
82. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-
derived mesenchymal stromal cells into osteoblasts
Hichame Id Boufker, Laurence Lagneaux, Mehdi Najar, Martine Piccart, Ghanem
Ghanem, Jean-Jacques Body, and Fabrice Journé
BMC Cancer. 2010;10:298.
PMCID: PMC3087319
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 13/29
83. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease,
incident CVD and mortality
Wolfgang Lieb, Philimon Gona, Martin G. Larson, Joseph M Massaro, Izabella
Lipinska, John F. Keaney, Jr, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S
Fox, Ramachandran S. Vasan, Emelia J. Benjamin, Christopher J O’Donnell, and
Sekar Kathiresan
Arteriosclerosis, thrombosis, and vascular biology. 2010;30(9):1849-1854.
PMCID: PMC3039214
84. Bone mineral density, bone turnover markers, lean mass, and fat mass in
Egyptian children with congenital adrenal hyperplasia
Soha M. Abd El Dayem, Ghada M. Anwar, Hassan Salama, Ashraf F. Kamel, and
Nahed Emara
Archives of Medical Science : AMS. 2010;6(1):104-110.
PMCID: PMC3278952
85. No significant effect on bone mineral density by high doses of vitamin D3 given to
overweight subjects for one year
Rolf Jorde, Monica Sneve, Peter A Torjesen, Yngve Figenschau, John-Bjarne
Hansen, and Guri Grimnes
Nutrition Journal. 2010;9:1.
PMCID: PMC2818614
86. Genome-Wide Association Meta-Analysis of Cortical Bone Mineral Density Unravels
Allelic Heterogeneity at the RANKL Locus and Potential Pleiotropic Effects on Bone
Lavinia Paternoster, Mattias Lorentzon, Liesbeth Vandenput, Magnus K. Karlsson,
Östen Ljunggren, Andreas Kindmark, Dan Mellstrom, John P. Kemp, Caroline E.
Jarett, Jeff M. P. Holly, Adrian Sayers, Beate St. Pourcain, Nicholas J. Timpson,
Panos Deloukas, George Davey Smith, Susan M. Ring, David M. Evans, Jon H.
Tobias, and Claes Ohlsson
PLoS Genetics. 2010;6(11):e1001217.
PMCID: PMC2987837
87. Circulating mediators of bone remodeling in psoriatic arthritis: implications for
disordered osteoclastogenesis and bone erosion
Nicola Dalbeth, Bregina Pool, Timothy Smith, Karen E Callon, Maria Lobo, William
J Taylor, Peter B Jones, Jillian Cornish, and Fiona M McQueen
Arthritis Research & Therapy. 2010;12(4):R164.
PMCID: PMC2945067
88. Bone Impairment in Phenylketonuria Is Characterized by Circulating Osteoclast
Precursors and Activated T Cell Increase
Ilaria Roato, Francesco Porta, Alessandro Mussa, Lucia D'Amico, Ludovica Fiore,
Davide Garelli, Marco Spada, and Riccardo Ferracini
PLoS ONE. 2010;5(11):e14167.
PMCID: PMC2994752
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 14/29
89. Biomarkers of the Osteoprotegerin Pathway: Clinical Correlates, Subclinical
Disease, Incident Cardiovascular Disease, and Mortality.
Wolfgang Lieb, Philimon Gona, Martin G. Larson, Joseph M. Massaro, Izabella
Lipinska, John F. Keaney, Jr, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S.
Fox, Ramachandran S. Vasan, Emelia J. Benjamin, Christopher J. O'Donnell, and
Sekar Kathiresan
Arterioscler Thromb Vasc Biol, Sep 2010; 30: 1849 - 1854.
PMID: 20448212
90. Persistent increase of osteoprotegerin levels after cortisol normalization in
patients with Cushing's syndrome.
Valentina Camozzi, Francesca Sanguin, Nora Albigier, Carla Scaroni, Franco
Mantero, Martina Zaninotto, Annachiara Frigo, Michele Piccolo, and Giovanni
Luisetto
Eur. J. Endocrinol., Jan 2010; 162: 85 - 90.
PMID: 19793762
91. Biomarkers in early rheumatoid arthritis: longitudinal associations with
inflammation and joint destruction measured by magnetic resonance imaging and
conventional radiographs.
Silje W Syversen, Espen A Haavardsholm, Pernille Bøyesen, Guro L Goll, Cecilie
Okkenhaug, Per Ivar Gaarder, Désirée van der Heijde, and Tore K Kvien
Ann Rheum Dis. 2010 May;69(5):845-50.
PMID: 20233753
92. Alendronate reduces osteoclast precursors in osteoporosis.
P D'Amelio, A Grimaldi, MA Cristofaro, M Ravazzoli, PA Molinatti, GP Pescarmona,
and GC Isaia
Osteoporos Int. 2010 Oct;21(10):1741-50.
PMID: 19949772
93. Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors,
Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after
Viral Hepatitis.
Jorge L. González-Calvin, Jose L. Mundi, Francisco J. Casado-Caballero, Ana C.
Abadia, and Jose J. Martin-Ibañez
J. Clin. Endocrinol. Metab., Dec 2009; 94: 4844 - 4850.
PMID: 19897681
94. ADA-deficient SCID is associated with a specific microenvironment and bone
phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency
Aisha V. Sauer, Emanuela Mrak, Raisa Jofra Hernandez, Elena Zacchi, Francesco
Cavani, Miriam Casiraghi, Eyal Grunebaum, Chaim M. Roifman, Maria C. Cervi,
Alessandro Ambrosi, Filippo Carlucci, Maria Grazia Roncarolo, Anna Villa,
Alessandro Rubinacci, and Alessandro Aiuti
Blood, Oct 2009; 114, 3216-3226.
PMID: 19633200
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 15/29
95. Non-association Between Polymorphisms of the Frizzled Receptor Genes and Bone
Mineral Density in Postmenopausal Korean Women
Jung Gu Kim, Hoon Kim, Byung Chul Jee, Chang Suk Suh, Young Min Choi, and
Shin Yong Moon
Journal of Korean Medical Science. 2009;24(3):443-447.
PMCID: PMC2698190
96. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α
agonist fenofibrate and the PPARγ agonist pioglitazone
Unni Syversen, Astrid K Stunes, Björn I Gustafsson, Karl J Obrant, Lars
Nordsletten, Rolf Berge, Liv Thommesen, and Janne E Reseland
BMC Endocrine Disorders. 2009;9:10.
PMCID: PMC2678137
97. Increased serum OPG in atrophic nonunion shaft fractures
Marchelli D, Piodi LP, Corradini C, Parravicini L, Verdoia C, Ulivieri FM.
Traumatology : Official Journal of the Italian Society of Orthopaedics and
Traumatology. 2009;10(2):55-58.
PMCID: PMC2688591
98. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts
Mizutani K, Sud S, Pienta KJ.
Journal of cellular biochemistry. 2009;106(4):563-569.
PMCID: PMC2776620
99. Bone Turnover and the Osteoprotegerin-RANKL Pathway in Tumor-Induced
Osteomalacia: A Longitudinal Study of Five Cases.
Domenico Rendina, Gianpaolo De Filippo, Libuse Tauchmanova, Luigi Insabato,
Riccardo Muscariello, Fernando Gianfrancesco, Teresa Esposito, Michele Cioffi,
Annamaria Colao, Pasquale Strazzullo, and Giuseppe Mossetti
Calcif Tissue Int, Sep 2009;
PMID: 19763378
100.
A 246-km continuous running race causes significant changes in bone
metabolism.
Katharina Kerschan-Schindl, Markus Thalmann, Gottfried H Sodeck, Katerina
Skenderi, Antonia L Matalas, Stephan Grampp, Christof Ebner, and Peter
Pietschmann
Bone. 2009 Dec;45(6):1079-83.
PMID: 19665602
101.
Chronic antiepileptic monotherapy, bone metabolism, and body composition in
non-institutionalized children.
Markus Rauchenzauner, Andrea Griesmacher, Tobias Tatarczyk, Edda Haberlandt,
Alexander Strasak, Lothar-Bernd Zimmerhackl, Gerda Falkensammer, Gerhard
Luef, and Wolfgang Hogler
Dev Med Child Neurol. 2010 Mar;52(3):283-8.
PMID: 19709134
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 16/29
102.
Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB
ligand: the Tromsø Study.
L Jorgensen, A Vik, N Emaus, J Brox, J-B Hansen, E Mathiesen, and P Vestergaard
Osteoporos Int. 2010 Jun;21(6):931-8.
PMID: 19701599
103.
The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL
in Patients with Paget's Disease of Bone.
S A Polyzos, A D Anastasilakis, Z Efstathiadou, M Kita, I Litsas, A Avramidis, G
Arsos, E Moralidis, S Gerou, V Pavlidou, A Papatheodorou, and E Terpos
Horm Metab Res. 2009 Nov;41(11):846-50.
PMID:19670154
104. Interleukin-17, RANKL, and osteoprotegerin
levels in gingival crevicular fluid from smoking and non-smoking patients with
chronic periodontitis during initial periodontal treatment.
N Buduneli, E Buduneli, and N Kutukculer
J Periodontol, Aug 2009; 80(8): 1274-80.
PMID: 19656027
105.
Osteoclastogenesis in Children with 21-hydroxylase Deficiency on Long Term
Glucocorticoid Therapy: The Role of RANKL/OPG Imbalance.
Giacomina Brunetti, Silvia Colucci, Laura Piacente, Maria Ciccarelli, Lucia Giordani,
Giovanni Carlo Del Vecchio, Massimo D'Amore, Livia Albanese, Luciano Cavallo,
and Maria Grano
J. Clin. Endocrinol. Metab., Jul 2009; 94:2269-2276.
PMID: 19401376
106.
The Clinical Significance of Serum Markers of Bone Turnover in NSCLC Patients:
Surveillance, Management and Prognostic Implications.
Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E,
Harrington KJ, Polyzos A, Syrigos KN.
Anticancer Res, May 2009; 29: 1651 - 1657.
PMID: 19443381
107.
Serum bone turnover markers may be involved in the metastatic potential of lung
cancer patients.
Eleni M Karapanagiotou, Evangelos Terpos, Kalliopi D Dilana, Christina Alamara,
Ioannis Gkiozos, Aris Polyzos, and Kostas N Syrigos
Med Oncol. 2010 Jun;27(2):332-8.
PMID: 19373566
Relationships between OPG, RANKL, bone metabolism, and bone mineral density
in biliary atresia.
S Honsawek, T Chaiwatanarat, P Vejchapipat, V Chongsrisawat, N Thawornsuk,
and Y Poovorawan
Pediatr Surg Int, Mar 2009; 25(3): 261-7.
PMID: 19184056
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 17/29
108.
Proinflammatory cytokines and receptor activator of nuclear factor kappaB-
ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's
disease.
N Turk, S Cukovic-Cavka, M Korsic, Z Turk, and B Vucelic
Eur J Gastroenterol Hepatol, Feb 2009; 21(2): 159-66.
109.
High osteoprotegerin serum levels in primary biliary cirrhosis are associated with
disease severity but not with the mRNA gene expression in liver tissue.
Nuria Guanabens, Anna Enjuanes, Luisa Alvarez, Pilar Peris, Llorenc Caballeria, M
Jesus Martinez de Osaba, Dacia Cerda, Anna Monegal, Francesca Pons, and Albert
Pares
J Bone Miner Metab. 2009;27(3):347-54.
PMID: 19229472
110.
Effect of Anti-Infective Mechanical Therapy on Clinical Parameters and Cytokine
Levels in Human Peri-Implant Diseases.
Poliana Mendes Duarte, Adriana Cutrim de Mendonca, Maria Beatriz Braz Maximo,
Vanessa Renata Santos, Marta Ferreira Bastos, and Francisco Humberto Nociti
J Periodontol, Feb 2009; 80(2): 234-243.
PMID: 19186963
111.
Dysregulated RANK Ligand/RANK Axis in Hyperhomocysteinemic Subjects: Effect
of Treatment With B-Vitamins.
Marit S. Nenseter, Thor Ueland, Kjetil Retterstøl, Ellen Strøm, Lars Mørkrid, Sverre
Landaas, Leiv Ose, Pål Aukrust, and Kirsten B. Holven
Stroke, Jan 2009; 40: 241 – 247
PMID: 19008470
112.
The HLA-B27 Transgenic Rat, a Model of Spondyloarthritis, Has Decreased Bone
Mineral Density and Increased RANKL to Osteoprotegerin mRNA Ratio.
Martina Rauner, Daniela Stupphann, Martin Haas, Ingrid Fert, Simon Glatigny,
Wolfgang Sipos, Maxime Breban, and Peter Pietschmann
J Rheumatol. 2009 Jan;36(1):120-6.
PMID: 19040304
113.
Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile
idiopathic arthritis: a bone damage biomarker?
P Spelling, E Bonfa, VF Caparbo, and RM Pereira
Scand J Rheumatol, Nov 2008; 37(6): 439-44.
PMID: 18802807
114.
Bone markers predict cardiovascular events in chronic kidney disease.
A Fahrleitner-Pammer, J Herberth, SR Browning, B Obermayer-Pietsch, G
Wirnsberger, H Holzer, H Dobnig, and HH Malluche
J Bone Miner Res. 2008 Nov;23(11):1850-8.
PMID: 18597636
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 18/29
115.
Modifying RANKL/OPG mRNA Expression in Differentiating and Growing Human
Primary Osteoblasts.
M Giner, M J Montoya, M A Vazquez, M J Rios, R Moruno, M J Miranda, and R
Perez-Cano
Horm Metab Res. 2008 Dec;40(12):869-74.
PMID: 18932123
116.
Bone remodeling biomarkers of periodontal disease in saliva.
BD Frodge, JL Ebersole, RJ Kryscio, MV Thomas, and CS Miller
J Periodontol. 2008 Oct;79(10):1913-9.
PMID: 18834246
117.
Serum osteoprotegerin concentrations are decreased in women with the polycystic
ovary syndrome.
Héctor F Escobar-Morreale, José I Botella-Carretero, Ma Ángeles Martínez-García,
Manuel Luque-Ramírez, Francisco Álvarez-Blasco, and José L San Millán
Eur. J. Endocrinol., Sep 2008; 159: 225 - 232.
PMID: 18579554
118.
Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in
healthy women and men.
K Kerschan-Schindl, J Wendlova, S Kudlacek, A Gleiss, W Woloszczuk, and P
Pietschmann
Exp Clin Endocrinol Diabetes, August 1, 2008; 116(8): 491-5.
PMID: 18072013
119.
α1β1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in
human T cells and enhance their osteoclastogenic function
Gendron S, Boisvert M, Chetoui N, Aoudjit F.
Immunology. 2008;125(3):359-369.
PMCID: PMC2669139
120.
Does Osteoprotegerin or Receptor Activator of Nuclear Factor-κB Ligand Mediate
the Association between Bone and Coronary Artery Calcification?
Bakhireva LN, Laughlin GA, Bettencourt R, Barrett-Connor E.
The Journal of Clinical Endocrinology and Metabolism. 2008;93(5):2009-2012.
PMCID: PMC2386279
121.
The differential expression of osteoprotegerin (OPG) and receptor activator of
nuclear factor κB ligand (RANKL) in human osteoarthritic subchondral bone
osteoblasts is an indicator of the metabolic state of these disease cells
Tat SK, Pelletier J-P, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J.
Clinical and experimental rheumatology. 2008;26(2):295-304.
PMCID: PMC5247261
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 19/29
122.
High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of
receptor activator of nuclear factor-kappaB ligand (RANKL) to OPG correlate with
disease severity in patients with primary knee osteoarthritis.
A Pilichou, I Papassotiriou, K Michalakakou, S Fessatou, E Fandridis, G
Papachristou, and E Terpos
Clin Biochem, Jun 2008; 41(9): 746-9.
PMID: 18355453
123.
OPG and sRANKL serum concentrations in osteopenic, postmenopausal women
after 2-year Genistein administration.
Herbert Marini, Letteria Minutoli, Francesca Polito, Alessandra Bitto, Domenica
Altavilla, Marco Atteritano, Agostino Gaudio, Susanna Mazzaferro, Alessia Frisina,
Nicola Frisina, Carla Lubrano, Michele Bonaiuto, Rosario D’Anna, Maria Letizia
Cannata, Francesco Corrado, Francesco Cancellieri, Marianna Faraci, Rolando
Marini, Elena Bianca Adamo, Steven Wilson, and Francesco Squadrito
JBMR, May 2008, Vol 23, No 5, 715-720
PMID: 18433304
124.
Osteoclast inhibitory effects of vitamin k2 alone or in combination with etidronate
or risedronate in patients with rheumatoid arthritis: 2-year results.
M Morishita, M Nagashima, K Wauke, H Takahashi, and K Takenouchi
J Rheumatol, Mar 2008; 35(3): 407-13.
PMID: 18260178
125.
Risedronate reduces osteoclast precursors and cytokine production in
postmenopausal osteoporotic women.
P D'Amelio, A Grimaldi, S Di Bella, C Tamone, SZ Brianza, MG Ravazzoli, P
Bernabei, MA Cristofaro, GP Pescarmona, and G Isaia
J Bone Miner Res, Mar 2008; 23(3): 373-9.
PMID: 17967134
126.
Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-
B ligand levels in women with established osteoporosis treated with teriparatide.
Athanasios D Anastasilakis, Dimirtios G Goulis, Stergios A Polyzos, Spiridon
Gerou, Vasiliki Pavlidou, George Koukoulis, and Avraam Avramidis
Eur. J. Endocrinol., Mar 2008; 158: 411 - 415.
127.
Does Osteoprotegerin or RANKL Mediate the Association Between Bone and
Coronary Artery Calcification?
Ludmila N. Bakhireva, Gail A. Laughlin, Ricki Bettencourt, and Elizabeth Barrett-
Connor
J. Clin. Endocrinol. Metab., Mar 2008; 10.1210/jc.2007-2624
PMCID: PMC2386279
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 20/29
128.
Effects of compression force on fibroblast growth factor-2 and receptor activator
of nuclear factor kappa B ligand production by periodontal ligament cells in vitro.
R Nakajima, M Yamaguchi, T Kojima, M Takano, and K Kasai
J Periodontal Res, Apr 2008; 43(2): 168-73.
PMID: 18302618
129.
Constitutional Thinness: Unusual Human Phenotype of Low Bone Quality.
Bogdan Galusca, Mohamed Zouch, Natacha Germain, Cecile Bossu, Delphine
Frere, Francois Lang, Marie-Helene Lafage-Proust, Thierry Thomas, Laurence Vico,
and Bruno Estour
J Clin Endocrinol Metab. January 2008, 93(1):110-117
PMID: 17956951
130.
Increased augmentation index and central aortic blood pressure in osteoporotic
postmenopausal women.
RA Mangiafico, C Alagona, P Pennisi, N Parisi, M Mangiafico, F Purrello, and CE
Fiore
Osteoporos Int, Jan 2008; 19(1): 49-56.
PMID: 17676381
131.
Bone mineral apparent density in juvenile dermatomyositis: the role of lean body
mass and glucocorticoid use.
RA Santiago, CA Silva, VF Caparbo, AM Sallum, and RM Pereira
Scand J Rheumatol, Jan 2008; 37(1): 40-7.
PMID: 18189194
132.
Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone
mineral density in healthy Chinese women.
HY Zhao, JM Liu, G Ning, YJ Zhao, Y Chen, LH Sun, LZ Zhang, MY Xu, and JL Chen
Osteoporos Int, Feb 2008; 19(2): 221-6.
PMID: 17703270
133.
The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin
Cytokine System in Primary Hyperparathyroidism
Inaam A. Nakchbandi, Robert Lang, Barbara Kinder, and Karl L. Insogna
J. Clin. Endocrinol. Metab., Dec 2007; 10.1210/jc.2007-1645.
PMCID: PMC2266956
134.
NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis
and expression of NFATc1 in mouse arthritis without affecting expression of
RANKL, osteoprotegerin or macrophage colony-stimulating factor
Kubota, T., Hoshino, M., Aoki, K., Ohya, K., Komano, Y., Nanki, T., Nobuyuki M.,
Umezawa, K.
Arthritis Research & Therapy, 9(5), R97.
PMCID: PMC2212584
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 21/29
135.
Serum Osteoprotegerin Concentration with Strontium Ranelate Treatment for
Postmenopausal Osteoporosis: An Open, Prospective Study
Ertorer ME, Bakiner O, Anaforoglu I, Sezgin N, Demirag NG, Tutuncu NB.
Current Therapeutic Research, Clinical and Experimental. 2007;68(4):217-225.
PMCID: PMC3967269
136. The Sex-Specific Association of Serum OPG and RANKL with Bone Mineral Density
in Older Adults: The Rancho Bernardo Study.
Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E.
European journal of endocrinology / European Federation of Endocrine Societies.
2007;156(5):555-562.
PMCID: PMC2642656
137. Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by
synovial fluids from patients with a loose joint prosthesis and from osteoarthritis
patients
Andersson MK, Lundberg P, Ohlin A, et al.
Arthritis Research & Therapy. 2007;9(1):R18. doi:10.1186/ar2127.
PMCID: PMC1860076
138.
Bone structure and metabolism in a rodent model of male senile osteoporosis.
P Pietschmann, M Skalicky, M Kneissel, M Rauner, G Hofbauer, D Stupphann, and
A Viidik
Exp Gerontol, Nov 2007; 42(11): 1099-108.
139.
Genetic background influences fluoride's effects on osteoclastogenesis.
D Yan, A Gurumurthy, M Wright, TW Pfeiler, EG Loboa, and ET Everett
Bone, Dec 2007; 41(6): 1036-44.
PMCID: PMC2238641
140.
Elevated soluble receptor activator of nuclear factor-kappaB ligand and reduced
bone mineral density in patients with adolescent idiopathic scoliosis.
KT Suh, SS Lee, SH Hwang, SJ Kim, and JS Lee
Eur Spine J, Oct 2007; 16(10): 1563-9.
PMCID: PMC2078303
141.
Expression of cathepsin-K in gingival crevicular fluid of patients with periodontitis.
M Mogi and J Otogoto
Arch Oral Biol, Sep 2007; 52(9): 894-8.
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 22/29
142.
Changes of OPG and RANKL concentrations in Crohn's disease after infliximab
therapy.
Pal Miheller, Gyorgyi Müzes, Karoly Racz, Anna Blazovits, Peter Lakatos, Laszlo
Herszenyi, and Zsolt Tulassay
Inflamm Bowel Dis. 2007 Nov;13(11):1379-84.
PMID: 17663430
143.
Soluble Receptor Activator of Nuclear Factor-B Ligand and Risk for Cardiovascular
Disease.
Stefan Kiechl, Georg Schett, Judith Schwaiger, Klaus Seppi, Paula Eder, Georg
Egger, Peter Santer, Agnes Mayr, Qingbo Xu, and Johann Willeit
Circulation, Jul 2007; 116: 385 - 391.
144.
Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients
with multiple myeloma. Clinical correlations.
V Goranova-Marinova, S Goranov, P Pavlov, and T Tzvetkova
Haematologica, Jul 2007; 92(7): 1000-1.
PMID: 17606458
145.
Juvenile Paget's disease: the second reported, oldest patient is homozygous for
the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates
circulating immunoreactive osteoprotegerin levels.
MP Whyte, PN Singhellakis, MB Petersen, M Davies, WG Totty, and S Mumm
J Bone Miner Res, Jun 2007; 22(6): 938-46.
PMID: 17352649
146.
Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered
bone metabolism and lower bone mass in hypercholesterolaemic subjects.
RA Mangiafico, G Malaponte, P Pennisi, G Li Volti, G Trovato, M Mangiafico, Y
Bevelacqua, F Mazza, and CE Fiore
J Intern Med, Jun 2007; 261(6): 587-96.
PMID: 17547714
147.
The sex-specific association of serum osteoprotegerin and receptor activator of
nuclear factor B legend with bone mineral density in older adults: the Rancho
Bernardo Study.
Anna Stern, Gail A Laughlin, Jaclyn Bergstrom, and Elizabeth Barrett-Connor
Eur. J. Endocrinol., May 2007; 156: 555 - 562.
PMCID: PMC2642656
148.
Alterations in circulating osteoimmune factors may be responsible for high bone
resorption rate in HIV-infected children and adolescents.
S Mora, I Zamproni, L Cafarelli, V Giacomet, P Erba, G Zuccotti, and A Vigano
AIDS, May 2007; 21(9): 1129-35.
PMID: 17502723
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 23/29
149.
Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic
liver transplantation: relationship with metabolic bone disease.
A Monegal, M Navasa, P Peris, L Alvarez, F Pons, J Rodes, and N Guanabens
Liver Int, May 2007; 27(4): 492-7.
PMID: 17403189
150.
The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis.
N Morabito, GT Russo, A Gaudio, A Lasco, A Catalano, E Morini, F Franchina, D
Maisano, M La Rosa, M Plota, A Crifo, A Meo, and N Frisina
Bone, Jun 2007; 40(6): 1588-94.
PMID: 17412659
151.
Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis
patients are unable to predict their responses to infliximab.
T. Lequerré, F. Jouen, M. Brazier, S. Clayssens, N. Klemmer, J.-F. Ménard, O.
Mejjad, A. Daragon, F. Tron, X. Le Loët, and O. Vittecoq
Rheumatology, Mar 2007; 46: 446 - 453.
PMID: 16899502
152.
RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated
juvenile dermatomyositis.
Kelly A Rouster-Stevens, Craig B Langman, Heather E Price, Roopa Seshadri,
Richard M Shore, Kathy Abbott, and Lauren M Pachman
Arthritis Rheum, Feb 2007; 56(3): 977-983.
PMID: 17328075
153.
Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in
patients with beta-thalassemia major.
NG Angelopoulos, A Goula, E Katounda, G Rombopoulos, V Kaltzidou, D Kaltsas, S
Malaktari, V Athanasiou, and G Tolis
J Bone Miner Metab, Jan 2007; 25(1): 60-7.
PMID: 17187195
154.
An increased osteoprotegerin serum release characterizes the early onset of
diabetes mellitus and may contribute to endothelial cell dysfunction.
Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C,
Capitani S, Zauli G.
Am J Pathol. 2006 Dec;169(6):2236-44.
PMCID: PMC1762477
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 24/29
155.
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-
kappaB ligand concentrations and normalises indices of bone remodeling in
patients with relapsed multiple myeloma.
Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli
A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.
Br J Haematol. 2006 Dec;135(5):688-92.
PMID: 17107351
156.
IL-7 Up-Regulates TNF-α-Dependent Osteoclastogenesis in Patients Affected by
Solid Tumor
Ilaria Roato, Giacomina Brunetti, Eva Gorassini, Maria Grano, Silvia Colucci, Lisa
Bonello, Lucio Buffoni, Roberto Manfredi, Enrico Ruffini, Davide Ottaviani, Libero
Ciuffreda, Antonio Mussa, and Riccardo Ferracini
PLoS ONE. 2006;1(1):e124.
PMCID: PMC1762428
157.
An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of
Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction
Paola Secchiero, Federica Corallini, Assunta Pandolfi, Agostino Consoli, Riccardo
Candido, Bruno Fabris, Claudio Celeghini, Silvano Capitani, and Giorgio Zauli
The American Journal of Pathology. 2006;169(6):2236-2244.
PMCID: PMC1762477
158.
Association of 12 serum biochemical markers of angiogenesis, tumour invasion
and bone turnover with bone metastases from breast cancer: a crossectional and
longitudinal evaluation
Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P.
British Journal of Cancer. 2006;95(4):506-514.
PMCID: PMC2360666
159.
Serum OPG and RANKL levels before and after intravenous bisphosphonate
treatment in Paget's disease of bone.
Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati, A,
De Paola V, Valleggi F, Nuti R.
Bone. 2007 Feb;40(2):457-63. Epub 2006 Sep 18.
PMID: 16979395
160.
Increased serum osteoprotegerin values in long-lived subjects: different effects of
inflammation and bone metabolism.
Mazziotti G, Amato G, Sorvillo F, Piscopo M, Rizzo MR, Lalli E, Iride L, Ciuffi M,
Molinari AM, Paolisso G, Carella C.
Eur J Endocrinol. 2006 Mar;154(3):373-7.
PMID: 19346738
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 25/29
161.
Association between phosphate removal and markers of bone turnover in
haemodialysis patients.
Albalate M, de la Piedra C, Fernandez C, Lefort M, Santana H, Hernando P,
Hernandez J, Caramelo C.
Nephrol Dial Transplant. 2006 Jun;21(6):1626-32.
PMID: 16490746
162.
Are activated T cells regulators of bone metabolism in children with Crohn
disease?
FA Sylvester, PM Davis, N Wyzga, JS Hyams, and T Lerer
J Pediatr, Apr 2006; 148(4): 461-6
PMID: 16647405
163.
High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in
Langerhans cell histiocytosis.
Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K,
Tsunematu Y, Fujimoto J, Imashuku S.
Pediatr Blood Cancer. 2006 Aug;47(2):194-9.
PMID: 16358318
164.
Bisphosphonate treatment does not affect serum levels of osteoprotegerin and
RANKL in hypercalcemic cancer patients.
Zojer N, Brenner K, Beke D, Kudlacek S, Hawa G, Woloszczuk W, Hofbauer LC,
Pecherstorfer M.
Anticancer Res. 2005 Sep-Oct;25(5):3607-12.
PMID: 16101188.
165.
Specific biochemical markers of bone metabolism and cytokine study confirm the
diagnosis of malignant infantile osteopetrosis at birth using cord blood sample.
Chan MH, Wong K, Chan IH, Luo YF, Tam S, Lam CW.
Pathology 37:1, 2005, 51 – 55
PMID: 15875734
166.
Low bone density and low serum levels of soluble RANK ligand are associated with
severe arterial calcification in patients with Takayasu arteritis.
Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM.
Rheumatology 2005 44(12):1503-1506
PMID: 16219645
167.
Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and
relationship with BMD assessed in female twins.
Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen
K, Langdahl BL.
Bone 2005 Apr;36(4):727-35
PMID: 15781001
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 26/29
168.
Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and
Experimental Heart Failure.
Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S,
Christensen G, Gullestad L, Aukrust P.
Circulation. 2005;111:2461-2468
PMID: 15883214
169.
The RANKL/OPG system is activated in inflammatory bowel disease and relates to
the state of bone loss.
Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H.
Gut 2005 54: 479-487
PMCID: PMC1774465
170.
Relationships between the changes of serum levels of OPG and RANKL with age,
menopause, bone biochemical markers and bone mineral density in Chinese
women aged 20-75.
Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL.
Calcif Tissue Int 2005 Jan;76(1):1-6
PMID: 15455183.
171.
Changes in osteoprotegerin/RANKL system, bone mineral density, and bone
biochemicals markers in patients with recent spinal cord injury.
Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E,
Ohanna F, Cristol JP, Rossi M, Leroux JL.
Calcif Tissue Int 2005 Jun;76(6):404-11
PMID: 15812577
172.
Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J,
Pons-Romero F.
Liver International 2005 25:2 305
PMID: 15780054
173.
Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL)
concentrations in normal children and in children with pubertal precocity, Turner's
syndrome and rheumatoid arthritis.
Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari
E, Cocchi D
Clin Endocrinol (Oxf). 2004 Jan;60(1):87-91.
PMID: 14678293
174.
Soluble RANKL and Risk of Nontraumatic Fracture.
Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A,
Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J.
JAMA.2004; 291:2703
PMID: 14996780
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 27/29
175.
Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor
RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease
patients
FRANCHIMONT, N., REENAERS, C., LAMBERT, C., BELAICHE, J., BOURS, V.,
MALAISE, M., DELVENNE P., LOUIS, E.
Clinical and Experimental Immunology, 2004 : 138(3), 491–498.
PMCID: PMC1809233
176.
Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of
Coronary Artery Disease in Men.
Schoppet M, Schaefer JR, Hofbauer LC.
Circulation. 2003 Mar 25;107(11):e76;
PMID: 12654623
177.
Serum osteoprotegerin but not receptor activator of NF-{kappa}B ligand
correlates with Larsen score in rheumatoid arthritis.
Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A.
Ann Rheum Dis 2004 63: 216-217
PMCID: PMC1754876
178.
Increased expression of receptor activator of NF-kappaB ligand (RANKL), its
receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's
disease patients.
Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, Delvenne
P, Louis E.
Clin Exp Immunol 2004 Dec;138(3):491-8
PMCID: PMC1809233
179.
Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in
rheumatoid arthritis: comparison with IL1ß and tumour necrosis factor.
Dai S, Nishioka K, Yudoh K.
Annals of the Rheumatic Diseases 2004;63:1379-1386
PMCID: PMC1754791
180.
Low bone density and abnormal bone turnover in patients with atherosclerosis of
peripheral vessels.
Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, Fiore CE.
Osteoporosis International 2004, 15:5, 389 – 395
PMID: 14661073
181.
Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK
ligand serum levels in healthy young women.
Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M.
Clinical Endocrinology 60:2 2004, p214
PMID: 14725683
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 28/29
182.
T cells support osteoclastogenesis in an in vitro model derived from human
multiple myeloma bone disease: the role of the OPG/TRAIL interaction.
Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R,
Liso A, Capalbo S, Liso V, Zallone A, Grano M.
Blood, 104:12, 2004. 3722-3730
PMID: 15308561
183.
OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis,
osteoarthritis and spondylarthropathy.
Krystufkova O, Niederlova J, Senolt V, Hladikova M, Ruzickova S, Vencovsky J.
Arthritis Res Ther 2003, 5(Suppl 1):102
PMCID: PMC2833669
184.
Receptor Activator of Nuclear Factor kß Ligand (RANKL)/Osteoprotegerin (OPG)
Ratio Is Increased in Severe Osteolysis.
Eva Grimaud, Luc Soubigou, Séverine Couillaud, Patrick Coipeau, Anne Moreau,
Norbert Passuti, François Gouin, Françoise Redini, and Dominique Heymann
American Journal of Pathology, Vol. 163, No. 5, 2003
PMCID: PMC1892410
185.
Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio
predicts survival in multiple myeloma: proposal for a novel prognostic index.
Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N,
Yataganas X, Goldman JM, Rahemtulla A.
Blood. 2003 Aug 1;102(3):1064-9.
PMID: 12689925.
186.
Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in
serum.
Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, Woloszczuk W.
Clin Lab. 2003;49(9-10):461-3
PMID: 14572201
187.
OPG and RANKL in serum and synovial fluids of patients with rheumatoid arthritis,
osteoarthritis and spondylarthropathy
Krystufkova O, Niederlova J, Senolt V, Hladikova M, Ruzickova S, Vencovsky J.
Arthritis Research & Therapy. 2003;5(Suppl 1):102.
PMCID: PMC2833669
188.
Unusual Association between Increased Bone Resorption and Presence of
Paroxysmal Nocturnal Hemoglobinuria Phenotype in Multiple Myeloma.
Terpos E, Samarkos M, Meletis C, Apostolidou E, Tsironi M, Korovesis K,
Mavrogianni D, Viniou N, Meletis J.
International Journal of Hematology 78: 4, 2003, 344 - 348
PMID: 14686493
BI-20462 free sRANKL ELISA References / Publications Developed and manufactured by BIOMEDICA
Last update March 2018
BIOMEDICA IMMUNOASSAYS – SETTING THE STANDARD FOR CLINICAL RESEARCH 29/29
189.
Effect of Anticoagulants and Storage Temperature on the Stability of Receptor
Activator for Nuclear Factor-B Ligand and Osteoprotegerin in Plasma and Serum.
Evans MJ, Livesey JH, Ellis MJ, Yandle TG.
Clin Chem 2003 49: 2083-2085.
PMID: 11311219
190.
Osteoprotegerin and sRANKL serum levels in multiple myeloma patients.
Barbara Kruk, Maria Kraj, Piotr Centkowski, Urszula Sokołowska
Centr Eur J Immunol 2002 ; 27 (4) : 129-135
191.
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B
ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone
disease.
Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S,
Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V.
Blood 2002 Dec 15;100(13):4615-21
PMID: 12393684